DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV

This is a pilot, open label, single-arm, single centre, phase 3, switch study exploring the safety of of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks in women of reproductive potential living with HIV-1 switched from Efavirenz or Dolutegravir-based antiretroviral therapy. The metabolic and neuropsychiatric outcomes among women (and their infants) in a representative African female population of reproductive potential will be investigated.

Approximately 100 women aged between 18 and 49 years old will be administered a once-daily, fixed-dose combination of doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg (DOR/3TC/TDF). The study includes screening and baseline visits, 4 study visits from Week 4 to Week 36, and an end of study visit at Week 48.

Inclusion criteria

• Females, aged 18-49 years and ≥ 40 kg
• On a first-line EFV or DTG-containing regimen for at least six months and not more than 3 years
• Plasma HIV-1 RNA < 50 copies/mL in last 60 days
• Calculated creatinine clearance (CrCl) > 50 mL/min (Cockcroft-Gault formula)
• Baseline weight measurement available at ART initiation.

Exclusion criteria

• Virological failure on any other regimen
• Women who are pregnant at the time of the screening or enrolment visits or have had a pregnancy gestation ≥ 28 weeks in the preceding 2 years
• Active tuberculosis and/or are on antituberculosis therapy at the time of the screening or enrolment visits
• Taking (and cannot discontinue) prohibited concomitant medications listed in protocol at least two weeks prior to the enrolment visit and for the duration of the study period (see potential drug interactions section for list).